Navigation Links
Beike Earns AABB Accreditation for Cord Blood and Cord Tissue Banking

SHENZHEN, China, May 29, 2012 /PRNewswire-Asia/ -- Beike Biotechnology  Co., Ltd ("Beike") announced that it has been awarded AABB accreditation for cord blood and cord tissue banking. This accreditation has been granted following an intensive on-site assessment by AABB assessors and establishes that the level of medical, technical and administrative performance within the facility is in accordance with the AABB standards or exceeds those set by AABB. With this achievement, Beike becomes China's first and only AABB-accredited stem cell bank for both cord blood and cord tissue banking.

Ying Song, MD, PhD, Medical Director of Beike, stated, "It is a proud moment for us that Beike is the first and the only stem cell bank in China to possess AABB accreditation for both cord blood and cord tissue and this reflects our commitment to quality. It is also noteworthy to mention that Beike is among the first stem cell banks in the world to receive AABB accreditation for cord tissue banking which positions Beike as a leader in stem cell preservation."

Beike began the comprehensive AABB accreditation process in March 2010 and completed the on-site assessment in September 2011. The accreditation assessment included stem cell processing, records, document control, inspection and testing, technician training, sample identification, traceability and validations. During this audit, it was determined that Beike's medical, technical and administrative performance met the standards set by the AABB. Beike was issued its AABB certificate in January 2012.

Dr. Shengqin Ye, President of Beike, commented, "We are extremely pleased to have been granted this accreditation. With this, Beike has once again demonstrated a commitment to advanced learning, continuous improvement and innovation to sustain the highest possible level of quality and safety."

To meet AABB standards, Beike adopted new technology for stem cell processing (AXP® AutoXpress system), storage (BioArchive® Systems), and testing (Beckman hematology analyzer LH750 and Tecan Freedom EVOlyzer). Additionally, the company optimized its information technology platform and software systems, adding an advanced bar code management system, real-time monitoring capabilities, and an advanced enterprise resource planning (ERP) system to its call center. 

About Beike Biotechnology Company:

Shenzhen Beike Biotechnology Co., Ltd. is China's leading biotechnology company focusing on banking adult stem cells and developing  new cell based medicinal products. Headquartered in Shenzhen (near Hong Kong) with a flagship regenerative medicine facility at the China Medical City in Jiangsu province, Beike produces a full line of stem cell products derived from umbilical cord, cord blood and autologous bone marrow.

About AABB:

AABB (formerly the American Association of Blood Banks) is an international non-profit body dedicated to developing the highest standards in blood and cord blood banking, transfusion medicine and cellular therapy. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety.

Based in the United States, AABB represents more than 2,000 institutions and 8,000 individuals in 80 countries, involved in collecting, processing, testing, distributing, or transfusing blood, blood components, or cellular therapy products.

For any questions regarding this release, please call:

Contact Person:
T. Gutmann
Phone Number: +86-532-6677-6659

SOURCE Beike Biotechnology Co. Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
2. Beike Biotech Adds International Executives to Strengthen Current Technologies and Develop Future Pipeline
3. Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials
4. Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India
5. Beike Biotechnology Opens Worlds Largest Stem Cell Storage and Processing Facility
6. Beike Biotechnology Opens First Chinese Rehabilitation Center in Romania
7. Aerospace engineer earns Oak Ridge Associated Universities Ralph Powe Junior Faculty Award
8. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
9. Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services
10. Professor-turned-producer learns the movie biz
11. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
Post Your Comments:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):